TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02748798
Drug: PFP
Normalized name: PFPE - Perfluoroalkylpolyether
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perfluoropropane (PFP) will be premixed and delivered to the participants with no further processing.
Study: NCT02748798
Drug: SF6
Normalized name: BENZALKONIUM CHLORIDE 0.13 mg in 100 mL TOPICAL LIQUID [PURELL SF607 Instant Hand Sanitizing]
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfur hexafluoride (SF6) will be premixed and delivered to the participant with no further processing.
Study: NCT01933152
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients with wet AMD treated with ranibizumab as prescribed by physician
Study: NCT02430714
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 24mg once daily oral dosing to Unresectable thyroid cancer patients
Study: NCT00121966
Drug: Insulin Aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00121966
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00121966
Drug: Rosiglitazone
Normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00944840
Drug: SP plus amodiaquine
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SP plus amodiaquine or placebo at monthly interval during September, October and November
Study: NCT00944840
Drug: SP placebo plus amodiaquine placebo
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: monthly treatment with amodiaquine and SP or placebo during September, October and November
Study: NCT00642759
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by infusion on day 1 of each 3 week cycle for a maximum of 6 cycles
Study: NCT00642759
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by infusion once weekly (days 1, 8 and 15) of each three week cycle for a maximum of 6 cycles
Study: NCT00642759
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion
Study: NCT02184286
Drug: Nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg q.d. days 1-14 followed by 200 mg b.i.d. days 15-28
Study: NCT02184286
Drug: Saquinavir-sgc
DrugBank: Saquinavir (DB01232)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1600 mg b.i.d. from pre trial to day 28
Study: NCT02781558
Drug: RBV
Normalized name: RBV
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT00322218
Drug: Zevalin
Normalized name: Zevalin KIT
DrugBank: Ibritumomab tiuxetan (DB00078)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zevalin study treatment regimen consisted of 2 rituximab i.v. infusions (Day 1 and Day 7-9) and one \[90Y\]-ibritumomab tiuxetan infusion in connection with the second rituximab infusion.~The core treatment regimen in the Zevalin arm was:~Day 1: Rituximab i.v. infusion 250 mg/m\^2~Day 7-to 9: Rituximab i.v. infusion 250 mg/m\^2 immediately followed by \[90Y\]-ibritumomab tiuxetan 14.8 MBq/kg (0.4 mCi/kg) with a maximum dose of 1184 MBq (32 mCi),administered as slow intravenous push over 10 minutes.
Study: NCT03272321
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Syntocinon nasal spray
Study: NCT00238329
Drug: thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02478281
Drug: Methylene Blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02731560
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab was administered as an intravenous infusion as per approved protocol on Day 1 and day 14. The protocol stipulated the administration of intravenous hydrocortisone 100 mg and oral pheniramine maleate 43.5 mg as pre-medication. The Rituximab itself was given as a 1 gm infusion slowly over a period of 4-6 hours.~This was done either by a specialist nurse or a trained doctor.
Study: NCT02123355
Drug: Induction of anesthesia
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Midazolam 0.05 mg/kg、Propofol 1.0 mg/kg、Sufentanyl 3μg/kg、Victracurium 0.1 mg/kg sequential intravenous injection
Study: NCT02123355
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine is given at 0.5μg/kg/h by continuous infusion and is stopped to given 30 minutes before the surgery is over.
Study: NCT02141282
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Each dose of venetoclax was to be taken with approximately 240 mL of water within 30 minutes after the completion of breakfast or the participant's first meal of the day.
Study: NCT01356147
Drug: Dornase alfa
Normalized name: Dornase Alfa
DrugBank: Dornase alfa (DB00003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 mg nebulized endotracheally every 12 hours for 7 days or until extubation
Study: NCT02516813
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants received Cisplatin twice at a dose of 100 mg/m\^2 or weekly at a dose of 40 mg/m\^2.
Study: NCT00055185
Drug: CD4-IgG2 (PRO 542)
Normalized name: lisocabtagene maraleucel
DrugBank: Lisocabtagene maraleucel (DB16582)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04280588
Drug: Fingolimod 0.5 mg
Normalized name: fingolimod 0.5 MG
DrugBank: Fingolimod (DB08868)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days
Study: NCT00391716
Drug: Gabapentin 900mg
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 900 mg gabapentin daily for 12 weeks
Study: NCT00391716
Drug: gabapentin 1800mg
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1800 mg gabapentin daily for 12 weeks
Study: NCT00349986
Drug: Insuline glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03830398
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The investigators apply paracetamol during a week in preoperative room 45 min before ECT
Study: NCT00834574
Drug: Cefdinir for oral suspension 250 mg/5mL
Normalized name: cefdinir Oral Suspension
DrugBank: Cefdinir (DB00535)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 x 250 mg/5mL, single dose fasting
Study: NCT02376010
Drug: rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02376010
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02068443
Drug: Alogliptin
Normalized name: Alogliptin
DrugBank: Alogliptin (DB06203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alogliptin tablets
Study: NCT02068443
Drug: Metformin hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin hydrochloride tablets
Study: NCT02068443
Drug: Metformin hydrochloride Placebo
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin hydrochloride placebo-matching tablets
Study: NCT00500331
Drug: pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active Control
Study: NCT00461890
Drug: Injectable Naltrexone
Normalized name: naltrexone Injection
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04161482
Drug: Furosemide 80 mg (8 mg/mL)
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furoscix will be administered as a subcutaneous infusion.
Study: NCT00205322
Drug: chemotherapy (capecitabine, oxaliplatin, 5-FU, leucovorin)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01242020
Drug: Perflutren Lipid Microsphere Injectable Suspension
DrugBank: Perflutren (DB00556)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.3 mL activated DEFINITY® diluted in 50 mL of preservative-free saline will be used
Study: NCT01986855
Drug: Ertugliflozin 5 mg
Normalized name: ertugliflozin 5 MG
DrugBank: Ertugliflozin (DB11827)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ertugliflozin, oral, 5 mg tablet once daily for 52 weeks
Study: NCT02317419
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: gemcitabine administered according to local label on Days 1, 8, and 15 of each 28-day cycle.
Study: NCT02317419
Drug: nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel administered according to the local label on Days 1, 8, and 15 of each 28-day cycle.
Study: NCT01986855
Drug: Ertugliflozin 10 mg
DrugBank: Ertugliflozin (DB11827)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ertugliflozin, oral, tablet, 10 mg tablet once daily for 52 weeks
Study: NCT01339091
Drug: Dalbavancin
Normalized name: Dalbavancin
DrugBank: Dalbavancin (DB06219)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV Dalbavancin 1000 mg on Day 1 and 500 mg on Day 8
Study: NCT01339091
Drug: Vancomycin / Linezolid
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Vancomycin (1 gram Q 12 hours or 15mg/Kg Q 12 hours) with optional switch to oral linezolid (600 mg Q12 hours). Total duration of therapy is 10-14 days.
Study: NCT02826681
Drug: Placebo (Normal Saline)
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline Solution
Study: NCT02738619
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1600 UI
Study: NCT00770679
Drug: lipitor
Normalized name: Lipitor
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg everyday (QD) for 3 weeks
Study: NCT01844700
Drug: Ziprasidone
Normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: random assignment to ZIP (20-160mg/d, bid dosing)
Study: NCT00336206
Drug: Alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01844700
Drug: aripiprazole, quetiapine, or risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: random assignement to Usual Care antipsychotic UC antipsychotic (aripiprazole 2-30mg/d, quetiapine 25-800mg/d or risperidone 0.1-8mg/d)
Study: NCT01817777
Drug: Metformin Small Pack
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A single small pack of metformin will consist of a blister package containing 10 pills with a patient information leaflet in local language. The small packs will be available at each site in the following doses: 500 mg, 850 mg, and 1000 mg. The small pack size of metformin is not yet marketed. Small pack metformin will be provided by GSK as GSK brand metformin.
Study: NCT01817777
Drug: Metformin Large Pack
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The large pack will consist of 1 month's supply of metformin.
Study: NCT04053387
Drug: tapinarof cream, 1%
DrugBank: Tapinarof (DB06083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent use of Tapinarof cream, 1%, applied once daily according to PGA score
Study: NCT04250792
Drug: Naltrexone Pill
Normalized name: naltrexone Pill
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: role of low dose naltrexone in patients affected with psoriasis
Study: NCT03680521
Drug: Sitravatinib
Normalized name: Sitravatinib
DrugBank: Sitravatinib (DB15036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitravatinib oral capsule administered daily for 6-8 weeks in segments 1 and 2.
Study: NCT03680521
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab administered as 240 mg IV every 2 weeks for 4-6 weeks in segment 2.
Study: NCT04398225
Drug: Centanafadine
Normalized name: Centanafadine
DrugBank: Centanafadine (DB14841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended release capsule
Study: NCT01718847
Drug: NOV120101 (Poziotinib)
Normalized name: Poziotinib
DrugBank: Poziotinib (DB12114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg PO once daily until disease progression or unacceptable toxicity development
Study: NCT01950923
Drug: sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02428881
Drug: onabotulinumtoxinA
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Patients received 100U onabotulinumtoxinA injection into the external urethral sphincter
Study: NCT03760185
Drug: Brimonidine Tartrate
Normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All subjects will apply brimonidine tartrate to one eye (right eye) only for the duration of study participation.
Study: NCT02559856
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02559856
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00002670
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02013648
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02013648
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02013648
Drug: Daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02013648
Drug: Idarubicin
Normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00488345
Drug: Tygacil
Normalized name: Tygacil
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02248233
Drug: Nimodipine
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Jiangsu Jichuan Pharmaceutical Co., Ltd., Jiangsu Province, China
Study: NCT02248233
Drug: Saline + citicoline
DrugBank: Citicoline (DB12153)
Approvals — FDA: no, EMA: no, PMDA: no
Description: physiological saline + citicoline 2.0 g, once a day, via intravenous drip, for 10 consecutive days.
Study: NCT03113344
Drug: cephalosporins,penicillins,macrolides,carbapenems and antiviral drugs
DrugBank: Carbapenem (DB18912)
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to the models of population pharmacokinetics,the investigators and want to correlate use of antibiotics with treatment effectiveness and safety in children.
Study: NCT00489398
Drug: epinastine HCL and olopatadine HCL
Normalized name: Epinastine Hydrochloride
DrugBank: Epinastine (DB00751)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03218553
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone : first dose : 0,2mg.kg-1 at the end of the surgical procedure, second dose (0,2 mg.kg-1) 24 hours after the surgery
Study: NCT00780910
Drug: MP-424
Normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 750 mg every 8 hours for 12 weeks
Study: NCT00780910
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 - 1000 mg/day based on body weight for 24 weeks
Study: NCT03277599
Drug: IV patient-controlled analgesia (PCA) tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol infusion (PCA): 400 mg tramadol, IV 4 mg/mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
Study: NCT03277599
Drug: ultrasound guided superficial cervical plexus block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ultrasound guided superficial cervical plexus blockage with 10 ml % 0.25 bupivacaine
Study: NCT03277599
Drug: ultrasound guided Great Auricular nerve block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ultrasound guided Great Auricular nerve blockage with 5 ml % 0.25 bupivacaine +IV patient-controlled analgesia (PCA) tramadol
Study: NCT01842256
Drug: Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * 3 Tablets (telmisartan 80mg, amlodipine 5mg, atorvastatin 40mg each one),~* oral intake, once in a period~* over the period Ⅰ\&Ⅱ(crossover)
Study: NCT01842256
Drug: atorvastatin 40mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 40MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * 1 Tablet (atorvastatin 40mg),~* oral intake, once in a period~* over the period Ⅰ\&Ⅱ(crossover)
Study: NCT03032484
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab is FDA approved as a treatment for recurrent Glioblastoma following failure of radiation therapy and temozolomide.
Study: NCT00141011
Drug: Ancrod (Viprinex)
Normalized name: ancrod
DrugBank: Ancrod (DB05099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.167 IU/kg/hr (0.6 mL/kg/hr) IV for 2-3 hours
Study: NCT00780910
Drug: Peginterferon Alfa-2b
Normalized name: Peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.5 mcg/kg/week for 24 weeks
Study: NCT04025957
Drug: SHR-1501
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously
Study: NCT04103814
Drug: magnesium-cannabidiolic acid cream
Normalized name: Cannabidiolic acid
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive Mg-CBDa (magnesium-cannabidiolic acid) cream for topical treatment of hallux rigidus or hallux valgus.
Study: NCT01928537
Drug: rigosertib sodium
Normalized name: Rigosertib
DrugBank: Rigosertib (DB12146)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00023595
Drug: Active Medication Alone
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medication for coronary artery disease and heart failure management.
Study: NCT01969409
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: i.v. rituximab given on two occasions 14 days apart.
Study: NCT06172023
Drug: Silver Nanoparticles Irrigant
DrugBank: Silver nitrate (DB11080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nanosilver irrigant solution
Study: NCT06172023
Drug: Chitosan Nanoparticles Irrigant
Normalized name: Chitosan
DrugBank: Chitosan low molecular weight (20-200 mpa.s) (DB14155)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitosan nanoparticles irrigant solution
Study: NCT01495013
Drug: 1mg Glimepiride/10mg Atorvastatin FDC
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet by mouth once a day
Study: NCT01495013
Drug: 2mg Glimepiride/10mg Atorvastatin FDC
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet by mouth once a day
Study: NCT01495013
Drug: 3mg Glimepiride/10mg Atorvastatin FDC
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet by mouth once a day
Study: NCT01495013
Drug: 4mg Glimepiride/10mg Atorvastatin FDC
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet by mouth once a day
Study: NCT01495013
Drug: 1mg Glimepiride/20mg Atorvastatin FDC
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet by mouth once a day
Study: NCT01495013
Drug: 2mg Glimepiride/20mg Atorvastatin FDC
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet by mouth once a day
Study: NCT01495013
Drug: 3mg Glimepiride/20mg Atorvastatin FDC
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet by mouth once a day
Study: NCT01495013
Drug: 4mg Glimepiride/20mg Atorvastatin FDC
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet by mouth once a day
Study: NCT01495013
Drug: 1mg Glimepiride
Normalized name: glimepiride 1 MG
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
Study: NCT01495013
Drug: 2mg Glimepiride
Normalized name: glimepiride 2 MG
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
Study: NCT01495013
Drug: 3mg Glimepiride
Normalized name: glimepiride 3 MG
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
Study: NCT01495013
Drug: 4mg Glimepiride
Normalized name: glimepiride 4 MG
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
Study: NCT01495013
Drug: 10mg Atorvastatin
Normalized name: atorvastatin 10 MG
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet of Atorvastatin and 1 tablet of Glimepiride co-administered once daily
Study: NCT01495013
Drug: 20mg Atorvastatin
Normalized name: atorvastatin 20 MG
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet of Atorvastatin and 1 tablet of Glimepiride co-administered once daily
Study: NCT00815633
Drug: Alefacept
Normalized name: Alefacept
DrugBank: Alefacept (DB00092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15mg intramuscular injection weekly for 12 weeks